Nuclease-resistant Double-stranded DNA Controls or Standards for Hepatitis B Virus Nucleic Acid Amplification Assays

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2009 Dec 23

PMID 20025781

Citations 6

Authors

Shuang Meng

Sien Zhan

Jinming Li

Affiliations

Soon will be listed here.

Abstract

Background: Identical blood samples tested using different kits can give markedly different hepatitis B virus (HBV) DNA levels, which can cause difficulty in the interpretation of viral load. A universal double-stranded DNA control or standard that can be used in all commercial HBV DNA nucleic acid amplification assay kits is urgently needed. By aligning all HBV genotypes (A-H), we found that the surface antigen gene and precore-core gene regions of HBV are the most conserved regions among the different HBV genotypes. We constructed a chimeric fragment by overlapping extension polymerase chain reaction and obtained a 1,349-bp HBVC+S fragment. We then packaged the fragment into lambda phages using a traditional lambda phage cloning procedure.

Results: The obtained armored DNA was resistant to DNase I digestion and was stable, noninfectious to humans, and could be easily extracted using commercial kits. More importantly, the armored DNA may be used with all HBV DNA nucleic acid amplification assay kits.

Conclusions: The lambda phage packaging system can be used as an excellent expression platform for armored DNA. The obtained armored DNA possessed all characteristics of an excellent positive control or standard. In addition, this armored DNA is likely to be appropriate for all commercial HBV DNA nucleic acid amplification detection kits. Thus, the constructed armored DNA can probably be used as a universal positive control or standard in HBV DNA assays.

Citing Articles

Design and Characterization of Compact, Programmable, Multistranded Nonimmunostimulatory Nucleic Acid Nanoparticles Suitable for Biomedical Applications.

Brumett R, Danai L, Coffman A, Radwan Y, Teter M, Hayth H Biochemistry. 2024; 63(3):312-325.

PMID: 38271599 PMC: 11587934. DOI: 10.1021/acs.biochem.3c00615.

Internal control for real-time polymerase chain reaction based on MS2 bacteriophage for RNA viruses diagnostics.

Zambenedetti M, Pavoni D, Dallabona A, Dominguez A, Poersch C, Fragoso S Mem Inst Oswaldo Cruz. 2017; 112(5):339-347.

PMID: 28403327 PMC: 5398160. DOI: 10.1590/0074-02760160380.

Design of virus-based nanomaterials for medicine, biotechnology, and energy.

Wen A, Steinmetz N Chem Soc Rev. 2016; 45(15):4074-126.

PMID: 27152673 PMC: 5068136. DOI: 10.1039/c5cs00287g.

Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma.

Chang L, Wang G, Jia T, Zhang L, Li Y, Han Y Oncotarget. 2016; 7(17):23988-4004.

PMID: 26992211 PMC: 5029679. DOI: 10.18632/oncotarget.8115.

Application of HTB-SiHa cells transfected with a recombinant plasmid for external quality assessment of Chlamydia trachomatis PCR.

Zhang K, Huo H, Sun Y, Wang L, Zhang R, Lin G Ann Lab Med. 2014; 34(5):360-6.

PMID: 25187888 PMC: 4151004. DOI: 10.3343/alm.2014.34.5.360.

References

WalkerPeach C, Pasloske B . DNA bacteriophage as controls for clinical viral testing. Clin Chem. 2004; 50(11):1970-1. PMC: 7108159. DOI: 10.1373/clinchem.2004.039776. View

Lole K, Arankalle V . Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. J Virol Methods. 2006; 135(1):83-90. DOI: 10.1016/j.jviromet.2006.02.004. View

Lai C, Ratziu V, Yuen M, Poynard T . Viral hepatitis B. Lancet. 2003; 362(9401):2089-94. DOI: 10.1016/S0140-6736(03)15108-2. View

Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A . Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res. 2003; 26(2):125-133. DOI: 10.1016/s1386-6346(03)00018-4. View

Heckman K, Pease L . Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc. 2007; 2(4):924-32. DOI: 10.1038/nprot.2007.132. View

Mommeja-Marin H, Mondou E, Blum M, Rousseau F . Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003; 37(6):1309-19. DOI: 10.1053/jhep.2003.50208. View

Wei Y, Yang C, Wei B, Huang J, Wang L, Meng S . RNase-resistant virus-like particles containing long chimeric RNA sequences produced by two-plasmid coexpression system. J Clin Microbiol. 2008; 46(5):1734-40. PMC: 2395109. DOI: 10.1128/JCM.02248-07. View

Paraskevis D, Haida C, Tassopoulos N, Raptopoulou M, Tsantoulas D, Papachristou H . Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J Virol Methods. 2002; 103(2):201-12. DOI: 10.1016/s0166-0934(02)00033-2. View

Masker W, Kuemmerle N, Allison D . In vitro packaging of bacteriophate T7 DNA synthesized in vitro. J Virol. 1978; 27(1):149-63. PMC: 354148. DOI: 10.1128/JVI.27.1.149-163.1978. View

10.

Kessler H . Comparison of currently available assays for detection of hepatitis B virus DNA in the routine diagnostic laboratory. Expert Rev Mol Diagn. 2005; 5(4):531-6. DOI: 10.1586/14737159.5.4.531. View

11.

Zaaijer H, Ter Borg F, Cuypers H, Hermus M, Lelie P . Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol. 1994; 32(9):2088-91. PMC: 263947. DOI: 10.1128/jcm.32.9.2088-2091.1994. View

12.

Heermann K, Gerlich W, Chudy M, Schaefer S, THOMSSEN R . Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol. 1998; 37(1):68-73. PMC: 84170. DOI: 10.1128/JCM.37.1.68-73.1999. View

13.

Yeon J . Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology. 2008; 51 Suppl 1:7-10. DOI: 10.1159/000122593. View

14.

Changotra H, Sehajpal P . Quantitative detection of serum HBV DNA levels employing a new S gene based cPCR assay. Arch Virol. 2005; 150(3):481-91. DOI: 10.1007/s00705-004-0432-6. View

15.

Lindh M, Hannoun C . Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay. J Clin Microbiol. 2005; 43(8):4251-4. PMC: 1233936. DOI: 10.1128/JCM.43.8.4251-4254.2005. View

16.

Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A . An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 2001; 80(1):63-71. DOI: 10.1046/j.1423-0410.2001.00003.x. View

17.

Hohn B, Murray K . Packaging recombinant DNA molecules into bacteriophage particles in vitro. Proc Natl Acad Sci U S A. 1977; 74(8):3259-63. PMC: 431522. DOI: 10.1073/pnas.74.8.3259. View

18.

Berger A, Preiser W, Doerr H . The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. J Clin Virol. 2001; 20(1-2):23-30. DOI: 10.1016/s1386-6532(00)00151-7. View

19.

Deiman B, Jay C, Zintilini C, Vermeer S, van Strijp D, Venema F . Efficient amplification with NASBA of hepatitis B virus, herpes simplex virus and methicillin resistant Staphylococcus aureus DNA. J Virol Methods. 2008; 151(2):283-293. DOI: 10.1016/j.jviromet.2008.04.009. View

20.

Shyamala V, Arcangel P, Cottrell J, Coit D, Medina-Selby A, McCoin C . Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays. J Clin Microbiol. 2004; 42(11):5199-204. PMC: 525161. DOI: 10.1128/JCM.42.11.5199-5204.2004. View